STAT+: Foundation charges cancer patients $83,000 for unproven but promising experimental drug
STAT News
MARCH 6, 2023
Determined to prove his doctors wrong, Aldrich got his tumor genetically sequenced and arranged for a German biotech, CeGaT, to design an experimental neoantigen vaccine that he received in 2019, according to Jacobs and an account Aldrich gave to an online cancer publication. “It really was a choice of this or nothing.”
Let's personalize your content